Certara (NASDAQ:CERT) Issues FY24 Earnings Guidance

Certara (NASDAQ:CERT) updated its FY24 earnings guidance on Tuesday. The company provided earnings per share guidance of $0.41-0.46 for the period, compared to the consensus earnings per share estimate of $0.43. The company issued revenue guidance of $385-400 million, compared to the consensus revenue estimate of $388.90 million.

Certara Stock Performance

NASDAQ:CERT traded up $0.57 on Thursday, reaching $16.92. 306,577 shares of the company’s stock were exchanged, compared to its average volume of 534,595. The firm has a market cap of $2.71 billion, a price-to-earnings ratio of -46.71, a P/E/G ratio of 1.81 and a beta of 1.61. The company has a debt-to-equity ratio of 0.28, a current ratio of 2.62 and a quick ratio of 2.62. The stock has a fifty day simple moving average of $17.71 and a 200-day simple moving average of $16.44. Certara has a 52 week low of $11.81 and a 52 week high of $22.65.

Certara (NASDAQ:CERT) last released its quarterly earnings data on Thursday, February 29th. The company reported $0.05 EPS for the quarter, missing the consensus estimate of $0.09 by ($0.04). Certara had a positive return on equity of 4.33% and a negative net margin of 15.62%. The business had revenue of $88.01 million during the quarter, compared to the consensus estimate of $86.80 million. As a group, sell-side analysts predict that Certara will post 0.29 earnings per share for the current year.

Analyst Upgrades and Downgrades

CERT has been the topic of a number of recent research reports. UBS Group increased their price objective on Certara from $17.00 to $20.00 and gave the stock a neutral rating in a report on Friday, March 1st. JMP Securities assumed coverage on shares of Certara in a report on Thursday, April 4th. They issued a market perform rating on the stock. Leerink Partnrs reaffirmed a market perform rating on shares of Certara in a research note on Monday, February 26th. KeyCorp upgraded shares of Certara from a sector weight rating to an overweight rating and set a $23.00 target price on the stock in a research note on Wednesday, April 10th. Finally, Barclays boosted their price target on shares of Certara from $16.00 to $18.00 and gave the company an equal weight rating in a research report on Thursday, January 25th. Seven equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat, Certara presently has a consensus rating of Hold and a consensus target price of $20.06.

Insider Transactions at Certara

In other Certara news, insider Patrick F. Smith sold 14,427 shares of the business’s stock in a transaction on Tuesday, April 2nd. The shares were sold at an average price of $16.85, for a total value of $243,094.95. Following the completion of the sale, the insider now directly owns 50,091 shares of the company’s stock, valued at $844,033.35. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Certara news, insider Patrick F. Smith sold 14,427 shares of the company’s stock in a transaction dated Tuesday, April 2nd. The shares were sold at an average price of $16.85, for a total value of $243,094.95. Following the sale, the insider now owns 50,091 shares in the company, valued at $844,033.35. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, SVP Richard M. Traynor sold 3,000 shares of the company’s stock in a transaction dated Monday, April 1st. The stock was sold at an average price of $18.00, for a total transaction of $54,000.00. Following the completion of the sale, the senior vice president now owns 173,524 shares in the company, valued at approximately $3,123,432. The disclosure for this sale can be found here. In the last ninety days, insiders sold 23,427 shares of company stock valued at $405,095. Insiders own 2.39% of the company’s stock.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.